Brokers Set Expectations for Krystal Biotech FY2025 Earnings

Key Points

• William Blair has lowered its FY2025 earnings per share (EPS) forecast for Krystal Biotech from $5.43 to $5.24, which is below the consensus estimate of $6.14.
• Krystal Biotech reported a quarterly EPS of $1.29, exceeding analysts' expectations of $1.08, with revenues of $96.04 million for the quarter.
• Analyst ratings for Krystal Biotech are mostly positive, with one hold, eight buy ratings, and a current consensus target price of $210.22.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at William Blair lowered their FY2025 earnings per share estimates for Krystal Biotech in a research report issued to clients and investors on Monday, August 4th. William Blair analyst S. Corwin now expects that the company will post earnings per share of $5.24 for the year, down from their previous estimate of $5.43. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q4 2025 earnings at $1.61 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.

A number of other equities analysts have also issued reports on KRYS. Chardan Capital reissued a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a report on Tuesday, August 5th. Citigroup reissued a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America lowered their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. HC Wainwright reissued a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Friday, July 25th. Finally, Guggenheim reduced their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech presently has an average rating of "Buy" and a consensus target price of $210.22.

Krystal Biotech Stock Performance

Shares of KRYS stock traded up $2.56 during mid-day trading on Wednesday, hitting $138.66. 332,066 shares of the stock were exchanged, compared to its average volume of 422,365. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84. The stock's fifty day simple moving average is $141.94 and its two-hundred day simple moving average is $155.38. The stock has a market capitalization of $4.01 billion, a price-to-earnings ratio of 28.18 and a beta of 0.70.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 in the last three months. 13.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. LPL Financial LLC lifted its position in shares of Krystal Biotech by 156.8% during the 4th quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after acquiring an additional 1,799 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Krystal Biotech by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after acquiring an additional 23,934 shares during the period. Alliancebernstein L.P. lifted its position in shares of Krystal Biotech by 4.7% during the 4th quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock valued at $4,875,000 after acquiring an additional 1,400 shares during the period. OLD Mission Capital LLC acquired a new stake in shares of Krystal Biotech during the 4th quarter valued at approximately $293,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Krystal Biotech during the 4th quarter worth approximately $1,529,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).